Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C27H31N9O15P2.2Na |
| Molecular Weight | 829.5134 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 7 / 7 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[Na+].CC1=C(C)C=C2N(C[C@H](O)[C@H](O)[C@H](O)COP([O-])(=O)OP([O-])(=O)OC[C@H]3O[C@H]([C@H](O)[C@@H]3O)N4C=NC5=C(N)N=CN=C45)C6=NC(=O)NC(=O)C6=NC2=C1
InChI
InChIKey=XLRHXNIVIZZOON-WFUPGROFSA-L
InChI=1S/C27H33N9O15P2.2Na/c1-10-3-12-13(4-11(10)2)35(24-18(32-12)25(42)34-27(43)33-24)5-14(37)19(39)15(38)6-48-52(44,45)51-53(46,47)49-7-16-20(40)21(41)26(50-16)36-9-31-17-22(28)29-8-30-23(17)36;;/h3-4,8-9,14-16,19-21,26,37-41H,5-7H2,1-2H3,(H,44,45)(H,46,47)(H2,28,29,30)(H,34,42,43);;/q;2*+1/p-2/t14-,15+,16+,19-,20+,21+,26+;;/m0../s1
| Molecular Formula | C27H31N9O15P2 |
| Molecular Weight | 783.5339 |
| Charge | -2 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 7 / 7 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | Na |
| Molecular Weight | 22.9898 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including:
http://www.wikidoc.org/index.php/FAD
http://www.drugbank.ca/drugs/DB03147
Curator's Comment: description was created based on several sources, including:
http://www.wikidoc.org/index.php/FAD
http://www.drugbank.ca/drugs/DB03147
Flavin adenine dinucleotide is a coenzyme form of vitamin B2. Many oxidoreductases, called flavoenzymes or flavoproteins, require FAD as a prosthetic group, which functions in electron transfers. It is usually used for the prevention and treatment of various diseases that are caused by Vitamin B2 deficiency or metabolic disorder including stomatitis, eczema, etc. No adverse reactions were reported.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | Flavitan Approved UseIt is usually used for the prevention and treatment of various diseases that are caused by Vitamin B2 deficiency Launch Date-9.9273597E10 |
|||
| Palliative | Flavitan Approved UseIt is an effective in conjunctivitis treatment. Launch Date-9.9273597E10 |
|||
| Palliative | Flavitan Approved UseIt is usually used for the prevention and treatment of metabolic disorder including stomatitis. Launch Date-9.9273597E10 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Flavin adenine dinucleotide concentration in erythrocytes with normal and deficient glucose-6-phosphate dehydrogenase. | 1970 Sep 1 |
|
| Mechanism of chlorpromazine-induced arrhythmia -- arrhythmia and mitochondrial dysfunction. | 1981 Jul |
|
| ACP1GUA-1--a low-activity variant of human erythrocyte acid phosphatase: association with increased glutathione reductase activity. | 1982 May |
|
| [Comparison of biochemical criteria for supplying the human body with riboflavin]. | 1991 Sep-Oct |
|
| Flavin adenine dinucleotide levels in erythrocytes of very low birthweight infants under vitamin supplementation. | 1993 |
|
| Determination of riboflavin and flavocoenzymes in human blood plasma by high-performance liquid chromatography. | 1995 |
|
| Cloning, heterologous expression, and enzymological characterization of human squalene monooxygenase. | 2000 Feb 15 |
|
| Mammalian augmenter of liver regeneration protein is a sulfhydryl oxidase. | 2001 Mar |
|
| Enzymatic and non-enzymatic reduction of brucine N-oxide by aldehyde oxidase and catalase. | 2001 Nov |
|
| Coordinated and reversible reduction of enzymes involved in terminal oxidative metabolism in skeletal muscle mitochondria from a riboflavin-responsive, multiple acyl-CoA dehydrogenase deficiency patient. | 2006 Mar |
|
| Identification and functional characterization of rat riboflavin transporter 2. | 2009 Apr |
Patents
Sample Use Guides
Oral: Take 5 to 45 mg of flavin adenine dinucleotide per day in 1 to 3 divided doses.
Injection: 40 mg one or two times per day
Route of Administration:
Other
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 09:30:19 UTC 2023
by
admin
on
Sat Dec 16 09:30:19 UTC 2023
|
| Record UNII |
67U7UHJ04C
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID0046723
Created by
admin on Sat Dec 16 09:30:19 UTC 2023 , Edited by admin on Sat Dec 16 09:30:19 UTC 2023
|
PRIMARY | |||
|
100000078480
Created by
admin on Sat Dec 16 09:30:19 UTC 2023 , Edited by admin on Sat Dec 16 09:30:19 UTC 2023
|
PRIMARY | |||
|
67U7UHJ04C
Created by
admin on Sat Dec 16 09:30:19 UTC 2023 , Edited by admin on Sat Dec 16 09:30:19 UTC 2023
|
PRIMARY | |||
|
DBSALT000903
Created by
admin on Sat Dec 16 09:30:19 UTC 2023 , Edited by admin on Sat Dec 16 09:30:19 UTC 2023
|
PRIMARY | |||
|
84366-81-4
Created by
admin on Sat Dec 16 09:30:19 UTC 2023 , Edited by admin on Sat Dec 16 09:30:19 UTC 2023
|
PRIMARY | |||
|
2734019
Created by
admin on Sat Dec 16 09:30:19 UTC 2023 , Edited by admin on Sat Dec 16 09:30:19 UTC 2023
|
PRIMARY | |||
|
SUB13893MIG
Created by
admin on Sat Dec 16 09:30:19 UTC 2023 , Edited by admin on Sat Dec 16 09:30:19 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |